PiggyBac-mediated Cancer Immunotherapy Using EBV-specific Cytotoxic T-cells Expressing HER2-specific Chimeric Antigen Receptor
Open Access
- 1 December 2011
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 19 (12) , 2133-2143
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- piggyBac Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage MalignanciesHuman Gene Therapy, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Multiplexed transposon-mediated stable gene transfer in human cellsProceedings of the National Academy of Sciences, 2010
- Genome-wide Mapping of PiggyBac Transposon Integrations in Primary Human T CellsJournal of Immunotherapy, 2009
- Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T LymphocytesJournal of Immunotherapy, 2009
- Virus-free induction of pluripotency and subsequent excision of reprogramming factorsNature, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell TransplantationTransplantation and Cellular Therapy, 2007
- PiggyBac Transposon-mediated Gene Transfer in Human CellsMolecular Therapy, 2007
- piggyBac is a flexible and highly active transposon as compared to Sleeping Beauty , Tol2 , and Mos1 in mammalian cellsProceedings of the National Academy of Sciences, 2006